Schroders

Schroders plc, established in 1804, is a global investment management firm headquartered in London. It offers a wide range of services, including asset management, advisory, and consultancy, catering to diverse clients such as financial institutions, high net worth individuals, pension plans, and government funds. Schroders manages assets across various classes like equities, fixed income, multi-asset, and alternatives, with a focus on creating long-term value for its clients. The firm employs over 3500 people worldwide, operating from 37 offices across 27 countries, and has a track record of stable ownership and long-term thinking in its approach to investing and client relationships.

Tim Creed

Head of Private Equity Investments and Global Investment Committee member

Jérôme Janssen

Co-Head of Infrastructure Equity Investment

Vahit Alili

Senior Investment Director

Past deals in Amsterdam

Healthy Workers

Seed Round in 2022
Healthy Workers B.V. is a company that focuses on developing business-to-business solutions aimed at fostering healthy work environments. Founded in 2016 and headquartered in Amsterdam, the Netherlands, the company offers products such as the WELLBEING-SCAN and an employer dashboard, which allow organizations to measure, analyze, and enhance employee well-being. Through its platform, Healthy Workers provides insights into various workplace factors, including engagement levels, physical and psychological stressors, and environmental conditions like temperature and humidity. The company also offers consultancy services related to productivity and workplace stressors, helping businesses create optimal working conditions. By leveraging data analytics and continuous feedback mechanisms, Healthy Workers supports organizations in achieving sustainable outcomes and improving overall employee satisfaction.

Cairn Real Estate

Acquisition in 2021
Cairn Real Estate is an independent investment manager based in Amsterdam. They specialize in managing various assets and investments strategically. With a focus on providing personalized and tailored solutions, Cairn Real Estate works to help clients achieve their financial objectives.

GeoSentric

Post in 2010
GeoSentric is a company based in Salo, Finland, and Amsterdam, The Netherlands, specializing in mobile digital lifestyle applications and geo-mobility social networking. Its flagship product, GyPSii, serves as a leading platform that connects people, places, and communities across various networks and devices. Utilizing patented technologies, GeoSentric facilitates the transfer and publishing of location-based information between mobile devices, enhancing user connectivity and engagement. The company operates in North America, Europe, and the Asia Pacific region, reflecting its global reach and commitment to innovation in the digital lifestyle and location services market.

GeoSentric

Series A in 2007
GeoSentric is a company based in Salo, Finland, and Amsterdam, The Netherlands, specializing in mobile digital lifestyle applications and geo-mobility social networking. Its flagship product, GyPSii, serves as a leading platform that connects people, places, and communities across various networks and devices. Utilizing patented technologies, GeoSentric facilitates the transfer and publishing of location-based information between mobile devices, enhancing user connectivity and engagement. The company operates in North America, Europe, and the Asia Pacific region, reflecting its global reach and commitment to innovation in the digital lifestyle and location services market.

Azafaros

Azafaros B.V., based in Leiden, the Netherlands, specializes in the development of therapeutic agents aimed at treating rare metabolic disorders, specifically lysosomal storage disorders. The company focuses on innovative oral medications made from aza-sugar compounds, which were originally discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC, and have been exclusively licensed to Azafaros. These promising therapeutic agents are designed to address critical disease pathways by targeting the central nervous system and altering the metabolism of glycosphingolipids through a unique dual mode of action. Azafaros seeks to improve patient outcomes and enhance the quality of life for individuals affected by these severe inherited conditions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.